Ortho Dermatologics has submitted a New Drug Application (NDA) to the U.S. FDA for IDP 118 (halobetasol propionate and tazarotene)...
Valeant Pharmaceuticals International, Inc. announced positive results from a Phase III, multicenter double-blind, randomized, vehicle-controlled clinical study to assess the...